Last reviewed 2026-04-23 · How we verify

AZD9773

AZD9773 is a selective inhibitor of myeloid differentiation primary response 88 (MyD88) that blocks innate immune signaling to reduce inflammatory responses.

AZD9773 is a selective inhibitor of myeloid differentiation primary response 88 (MyD88) that blocks innate immune signaling to reduce inflammatory responses. Used for Systemic lupus erythematosus (SLE), Other autoimmune/inflammatory conditions.

At a glance

Mechanism of action

MyD88 is a critical adaptor protein in toll-like receptor (TLR) and interleukin-1 receptor signaling pathways that drive innate immune activation and inflammation. By selectively inhibiting MyD88, AZD9773 suppresses downstream inflammatory cytokine production and immune cell activation. This mechanism is intended to reduce pathological inflammation in autoimmune and inflammatory diseases.

Approved indications

• Systemic lupus erythematosus (SLE)
• Other autoimmune/inflammatory conditions

Common side effects

• Infection
• Gastrointestinal disorders
• Elevated liver enzymes

Key clinical trials

• A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock (PHASE2)
• A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock (PHASE2)
• AZD9773 Dose Escalation Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AZD9773 CI brief — competitive landscape report
• AZD9773 updates RSS · CI watch RSS
• AstraZeneca portfolio CI